Insiders have been buying shares of Dish Network Corp. at current prices, suggesting they have confidence in the company. Good morning Wake-Up Watchlisters! While you're taking that shot of apple cider vinegar you'll see stock futures slid Tuesday morning as euro-zone inflation sped to a fresh all-time high. With rate hikes in full swing in the US and UK, the European Central Bank is preparing to lift borrowing costs as well. But there are ways to work volatility in your favor. One of our favorite strategies is Overnight Plays. These are quick, simple trades our Trade of the Day members have made as much as 340% gains on – all in less than 24 hours! Click here to see how they work. Here's a look at the top-moving stocks this morning. Dish Network Corp. (Nasdaq: DISH) DISH Network Corp. is up 5.20% premarket as there's reason to be optimistic about the company's future. Multiple insiders have substantially increased their holdings of DISH over the last 12 months. They've been buying shares at current prices, suggesting they have confidence in the company. Keep an eye on Dish going forward. Gap, Inc. (NYSE: GPS) Gap is down 3.28% premarket as supply chains and persistent delays continue to affect the clothing retailers outlook. Gap posted a wider-than-expected first quarter loss last week while slashing its full-year profit forecast. For the three months ending in April, Gap posted a loss of 44 cents per share on revenues of $3.5 billion. Gap is looking volatile right now. Duck Creek Technologies (Nasdaq: DCT)Duck Creek Technologies is up 4.17% premarket as the SAAS company was recently upgraded to "Strong Buy" in the Zacks Computer and Technology sector. The current-year estimates for the company have been revised up to 400% over the past year, and 2023 is on track for 40% growth. Keep an eye on Duck Creek Technologies going forward. Mirati Therapeutics (Nasdaq: MRTX) Mirati Therapeutics is down 3.08% premarket as analysts downgraded their forecasts for this year. Revenue estimates were cut sharply as the analysts signaled a weaker outlook. The consensus from Mirati Therapeutics' 13 analysts is for revenues of $8.2 million in 2022, which would reflect a 89% decline in sales compared to last year. Mirati is looking uncertain overall. You Need This Info For This Market If this isn't a bear market, we don't know what is. Our own Karim Rahemtulla shows in this video how you need to be in protective mode, but also still invest. This is one of the most important strategies for locking in gains during times of volatility. Click here to watch the video. Those are the top market movers today. Happy trading! The Wake-Up Watchlist Research Team | 
Post a Comment
Post a Comment